Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients

Tran-Der Tan, Lun-Wei Chiou, An-Chen Feng et al. Nov 03, 2025 pp. 1683-1683 10.1182/blood-2025-1683

Abstract Background The standard treatment of transplant-eligible acute myeloid leukemia is intensive anthracycline plus...

Tumor necrosis factor-alpha (TNFα) drives pathologic platelet hyperreactivity through signaling on hematopoietic stem/progenitor cells and expansion of canonical megakaryocytic progenitors.

Joshua Siner, Molly Brakhane, Katrina Ashworth et al. Nov 03, 2025 pp. 1250-1250 10.1182/blood-2025-1250

Abstract Tumor necrosis factor-alpha (TNFα) has multiple roles for signaling inflammation and its two receptors, TNFαR1 and TNFαR2 exhibit a...

Functional analyses of vitt patient-derived PF4-antibodies and adenoviral vaccine compounds reveal unique patient-specific profiles of multicellular activation

Romy Meier, Carolien Zeelen, Britta Naus et al. Nov 03, 2025 pp. 424-424 10.1182/blood-2025-424

Abstract Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare but life-threatening adverse reaction to COVID-19 vaccines resulting i...

Characterization of patients with restrictive patterns of lung disease following allogeneic hematopoietic stem cell transplantation

Gunjan Gaur, Zhenmei Zhang, Hemang Yadav Nov 03, 2025 pp. 6064-6064 10.1182/blood-2025-6064

Abstract Background: As mounting numbers of patients receive allogeneic hematopoetic stem cell transplantation (allo-SCT) for hematologic ma...

Multi-dimensional transcriptomic profiling reveals novel tumor microenvironment landscape and subtype-specific therapeutic Vulnerabilities of MALT lymphomas

Yijun Wu, Kai Kang, Xu Sun et al. Nov 03, 2025 pp. 1751-1751 10.1182/blood-2025-1751

Abstract Introduction: Mucosa-associated lymphoid tissue (MALT) lymphoma is the most prevalent subtype of marginal zone lymphomas and can pr...

Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute

Sabrina Testa, Akiko Shimamura, Junne Kamihara et al. Nov 03, 2025 pp. 3213-3213 10.1182/blood-2025-3213

Abstract Introduction Germline genetic testing is increasingly recommended at the time of a pediatric cancer diagnosis for children with soli...

Clinicopathological features and prognostic analysis of non-Hodgkin's lymphoma with paraproteins: A single-center retrospective study

Liao Wang, Shuling Hou Nov 03, 2025 pp. 7184-7184 10.1182/blood-2025-7184

Abstract Objective: In the 5th edition of the WHO Classification of Haematolymphoid Tumors (WHO-HAEM5), other diseases with paraproteins tha...

Assessing the impact of distance from primary hemophilia treatment center on annualized bleeding rates in people with inheritable bleeding disorders

Deeksha Katoch, Kaitlin Maciejewski, Hung-Mo Lin et al. Nov 03, 2025 pp. 1093-1093 10.1182/blood-2025-1093

Abstract Introduction: Access to federally-supported hemophilia treatment centers (HTC) is critically important in people with inheritable b...

Embedding narrative medicine into subspecialty training: A novel clinical rotation to foster humanism, empathy, and systems awareness

Andrew Freiberg, Matthew Darok, Maria Holstrom-Mercader et al. Nov 03, 2025 pp. 4643-4643 10.1182/blood-2025-4643

Abstract Introduction Across medical subspecialties—including hematology—there is rising concern about declining empathy...

A single-institution retrospective analysis of allo-HSCT for relapsed and refractory aggressive lymphomas: T-cell origin predicts better outcomes even in active disease.

Futoshi Yoshino, Daisuke Kaji, Mika Kuno et al. Nov 03, 2025 pp. 7822-7822 10.1182/blood-2025-7822

Abstract Introduction: Relapsed and refractory (r/r) aggressive lymphoma remains a therapeutic challenge. In recent years, chimeric antigen...

Efficacy of levetiracetam prophylaxis in blinatumomab-induced neuro-toxicities in acute lymphoblastic leukemia: Retrospective single-arm cohort study

Ali Gillani, Minhal Fatir, Ali Mirza et al. Nov 03, 2025 pp. 6838-6838 10.1182/blood-2025-6838

Abstract Background: Blinatumomab, a CD19x3 bispecific T cell engager, shows efficacy for B-cell acute lymphoblastic leu...

Etiologic heterogeneity in secondary hemophagocytic lymphohistiocytosis: A retrospective real-world study from a quaternary academic center

Asfand Yar Cheema, Akram Abushamma, Aashray Mandala et al. Nov 03, 2025 pp. 6547-6547 10.1182/blood-2025-6547

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome marked by excessive immune activati...

Mass spectrometry-based molecular investigation identifies key proteins involved in synergistic AXL and BCL-2 dual inhibition for Acute Myeloid Leukemia

Hongyu Guo, Aicha Houfani, YuMing Shi et al. Nov 03, 2025 pp. 6789-6789 10.1182/blood-2025-6789

Abstract Background The 5-year survival rate for AML patients remains around 30%, with drug resistance being a significant challenge. Overex...

The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis

Jiayi Ren, Wu Shishuang, Kai Qing et al. Nov 03, 2025 pp. 6550-6550 10.1182/blood-2025-6550

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is a severe disease incited by an inflammatory cytokine s...

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar et al. Nov 03, 2025 pp. 1672-1672 10.1182/blood-2025-1672

Abstract Context: FLT3 mutated (FLT3m) AML with co-occurring mutations in DNMT3a and NPM1 (triple mutated) have been identified to be a subs...

Butyrate up-regulates the expression of CDKN1A to block the cell cycle and inhibits the PI3K-AKT signaling pathway to promote apoptosis to play an anti-Acute Myeloid Leukemia role

Shujuan An, Xiao Tang, Yuancheng Guo et al. Nov 03, 2025 pp. 3285-3285 10.1182/blood-2025-3285

Abstract BACKGROUND Our previous research indicated a significant reduction in the beneficial metabolite butyrate acid,...

Toxicity and efficacy profile of cardioprotective vs conventional doxorubicin: A meta-analysis

Evani Jain, Anirudh Jain, Chiranjeevi Sainatham et al. Nov 03, 2025 pp. 6167-6167 10.1182/blood-2025-6167

Abstract INTRODUCTION: Anthracycline induced toxicity is a well known consequence of dose related cumulative effects accounting to cardiotox...

Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy

James Essell, Mustafa Ascha, Eric Schaefer et al. Nov 03, 2025 pp. 131-131 10.1182/blood-2025-131

Abstract Background: In patients with hematological malignancies, infections due to treatment toxicities or underlying disease are a common...

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

Lingxu Jiang, Li Ye, Xin Huang et al. Nov 03, 2025 pp. 3833-3833 10.1182/blood-2025-3833

Abstract Background TP53 mutations were common genomic alterations in myelodysplastic neoplasms (MDS) and associated with adverse prognosis....

Functional classification of monoallelic TP53 mutations refines prognostic stratification in myelodysplastic neoplasms

Alexander Streuer, Vladimir Riabov, Yotaro Ochi et al. Nov 03, 2025 pp. 3835-3835 10.1182/blood-2025-3835

Abstract Introduction Myelodysplastic neoplasms (MDS) are a group of hematological disorders characterized by ineffectiv...

Digital PCR-based dynamic monitoring of JAK2V617F burden: A decade-long study unravels its prognostic value in MPN treatment response

Hao Cai, Long Chang, Jian Li et al. Nov 03, 2025 pp. 5597-5597 10.1182/blood-2025-5597

Abstract Background: The JAK2V617F mutation is a key driver mutation in myeloproliferative neoplasms (MPNs), and its dynamic changes may ref...

Trends in triplet and quadruplet regimen utilization among patients with newly diagnosed multiple myeloma during 2017-2024

Hamlet Gasoyan, Michael Rothberg, Jeffrey Kovach et al. Nov 03, 2025 pp. 2626-2626 10.1182/blood-2025-2626

Abstract Background: Treatment options for multiple myeloma have evolved rapidly, but little is known about the trends in novel triplet and...

Harnessing BCL2 inhibition with BTK inhibition in follicular lymphoma: A translational trial with mechanistic insights from single cell analysis

Pin Lu, Tingwei Guo, YunYun Zhou et al. Nov 03, 2025 pp. 3313-3313 10.1182/blood-2025-3313

Abstract Background: Follicular lymphoma (FL), the most common indolent non-Hodgkin lymphoma, remains incurable despite initial responsivenes...

Molecular risk stratification of myelodysplastic syndromes in Brazil: A cohort applying IPSS-m and taxonomic classification

Frederico Honorato, Elvira Velloso, Paulo Campregher et al. Nov 03, 2025 pp. 7372-7372 10.1182/blood-2025-7372

Abstract Myelodysplastic syndromes (MDS) remain underrepresented in epidemiologic research from Latin America. Large studies such as Belli e...

RNA editing of H19 shapes hematopoietic stem cell function and differentiation via cell cycle regulation

Shuangshuang Pu, Liu He, Jia Yu et al. Nov 03, 2025 pp. 1380-1380 10.1182/blood-2025-1380

Abstract Adenosine-to-inosine (A-to-I) RNA editing is a key post-transcriptional modification involved in immune response and cell fate dete...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page